Comparison · NCT01189890-8a3b4be6
Sitagliptin vs Glimepiride: Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sitagliptin vs Glimepiride: Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30. Trial comparisons, record NCT01189890-8a3b4be6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01189890-8a3b4be6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0083 | 0.00228 | 0.0297 | wilson | |
| Risk in group 2 | 0.0466 | 0.0262 | 0.0815 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0383 | -0.0737 | -0.00872 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.178 | 0.0399 | 0.795 | log | |
| Odds ratio, group 1 over group 2 | 0.171 | 0.0375 | 0.781 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sitagliptin than on Glimepiride | 26.1 | 13.6 | 115 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sitagliptin | Sitagliptin phosphate 100 mg once daily (QD) or 50 mg QD | 2 | 241 | OG000 |
| Group 2 | Glimepiride | Glimepiride 1-6 mg QD | 11 | 236 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30
- Description
Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.
- Time frame
- Up to Week 30
- Population
- All randomized participants who received at least one dose of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
- NCT number
- NCT01189890
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- sitagliptin phosphate, Glimepiride, Placebo to Sitagliptin, Placebo to Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2013-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01189890?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01189890-8a3b4be6